Search
Displaying results 21 - 30 of 52 in total
Recurrent platinum drug resistant primary peritoneal cancer
go.drugbank.com/conditions/DBCOND0020559Drugs: BevacizumabUnresectable Non-Squamous Non-Small Cell Lung Cancer
go.drugbank.com/conditions/DBCOND0128120Drugs: BevacizumabRelacorilant
go.drugbank.com/drugs/DB14976ApprovedInvestigationalRelacorilant is a first-in-class, selective glucocorticoid receptor antagonist. Originally investigated to manage the metabolic and endocrinologic complications of hypercortisolism, such as Cushing’s syndrome, its clinical utility has pi...
Persistent Cervical Cancer
go.drugbank.com/conditions/DBCOND0125497Recurrent platinum sensitive primary peritoneal cancer
go.drugbank.com/conditions/DBCOND0128091Dilpacimab
go.drugbank.com/drugs/DB16140Investigational, Oxaliplatin and Bevacizumab). … Dilpacimab is under investigation in clinical trial NCT03368859 (A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine
Recurrent Cervical Cancer
go.drugbank.com/conditions/DBCOND0028795Etirinotecan pegol
go.drugbank.com/drugs/DB14951InvestigationalEtirinotecan pegol is under investigation in clinical trial NCT01663012 (Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma).
Locally advanced nonsquamous non-small cell lung cancer
go.drugbank.com/conditions/DBCOND0022054Metastatic Hepatocellular Carcinoma
go.drugbank.com/conditions/DBCOND0041971